139 related articles for article (PubMed ID: 12006538)
1. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
[TBL] [Abstract][Full Text] [Related]
2. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
Buller RE; Lallas TA; Shahin MS; Sood AK; Hatterman-Zogg M; Anderson B; Sorosky JI; Kirby PA
Clin Cancer Res; 2001 Apr; 7(4):831-8. PubMed ID: 11309330
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
[TBL] [Abstract][Full Text] [Related]
4. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 mutations in familial ovarian cancer.
Lallas TA; Buekers TE; Buller RE
Mol Genet Metab; 1999 Aug; 67(4):357-63. PubMed ID: 10444347
[TBL] [Abstract][Full Text] [Related]
7. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
Aghmesheh M; Nesland JM; Kaern J; Dorum A; Edwards L; Byth K; Friedlander M; Jackson P; Tucker KM; Russell PJ
Gynecol Oncol; 2004 Dec; 95(3):430-6. PubMed ID: 15581943
[TBL] [Abstract][Full Text] [Related]
8. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP).
Geisler JP; Hatterman-Zogg MA; Rathe JA; Lallas TA; Kirby P; Buller RE
Hum Mutat; 2001 Oct; 18(4):337-44. PubMed ID: 11668617
[TBL] [Abstract][Full Text] [Related]
10. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer.
Liu Z; Wang LE; Wang L; Lu KH; Mills GB; Bondy ML; Wei Q
Clin Cancer Res; 2005 Jul; 11(13):4968-76. PubMed ID: 16000597
[TBL] [Abstract][Full Text] [Related]
11. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
[TBL] [Abstract][Full Text] [Related]
12. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.
Goldberg I; Davidson B; Reich R; Gotlieb WH; Ben-Baruch G; Bryne M; Berner A; Nesland JM; Kopolovic J
Clin Cancer Res; 2001 Dec; 7(12):4073-9. PubMed ID: 11751504
[TBL] [Abstract][Full Text] [Related]
13. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
[TBL] [Abstract][Full Text] [Related]
15. Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families.
Kim TJ; Lee KM; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
Oncol Rep; 2006 Mar; 15(3):565-9. PubMed ID: 16465413
[TBL] [Abstract][Full Text] [Related]
16. Survival of BRCA1 negative ovarian cancer patients based on family history.
Chu CS; Morgan MA; Randall TC; Bandera CA; Rubin SC
Gynecol Oncol; 2001 Oct; 83(1):109-14. PubMed ID: 11585421
[TBL] [Abstract][Full Text] [Related]
17. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families.
Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG
Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006
[TBL] [Abstract][Full Text] [Related]
18. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
